Hanne Merritt
Maze (United States)(US)
Publications by Year
Research Areas
Melanoma and MAPK Pathways, Lysosomal Storage Disorders Research, Carbohydrate Chemistry and Synthesis, Glycogen Storage Diseases and Myoclonus, Cancer Mechanisms and Therapy
Most-Cited Works
- → Isolation of Picomolar Affinity Anti-c-erbB-2 Single-chain Fv by Molecular Evolution of the Complementarity Determining Regions in the Center of the Antibody Binding Site(1996)382 cited
- → Identification of NVP-BKM120 as a Potent, Selective, Orally Bioavailable Class I PI3 Kinase Inhibitor for Treating Cancer(2011)249 cited
- → RAF Inhibitors Activate the MAPK Pathway by Relieving Inhibitory Autophosphorylation(2013)123 cited
- → Abstract 3790: Preclinical profile of LGX818: A potent and selective RAF kinase inhibitor(2012)53 cited
- → Design and Discovery of N-(2-Methyl-5′-morpholino-6′-((tetrahydro-2H-pyran-4-yl)oxy)-[3,3′-bipyridin]-5-yl)-3-(trifluoromethyl)benzamide (RAF709): A Potent, Selective, and Efficacious RAF Inhibitor Targeting RAS Mutant Cancers(2017)44 cited
- → Two Distinct Mechanisms of Inhibition of LpxA Acyltransferase Essential for Lipopolysaccharide Biosynthesis(2020)39 cited
- → Design and Discovery of N-(3-(2-(2-Hydroxyethoxy)-6-morpholinopyridin-4-yl)-4-methylphenyl)-2-(trifluoromethyl)isonicotinamide, a Selective, Efficacious, and Well-Tolerated RAF Inhibitor Targeting RAS Mutant Cancers: The Path to the Clinic(2019)38 cited
- → Identification and structure–activity relationship of 2-morpholino 6-(3-hydroxyphenyl) pyrimidines, a class of potent and selective PI3 kinase inhibitors(2010)30 cited
- → Small-molecule inhibition of glycogen synthase 1 for the treatment of Pompe disease and other glycogen storage disorders(2024)30 cited
- → Discovery of imidazo[1,2-a]-pyridine inhibitors of pan-PI3 kinases that are efficacious in a mouse xenograft model(2016)27 cited